Compelo Medical Devices - Latest industry news and analysis is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More
Close
Dismiss

Ablynx Reports Study Results For Its Anti-thrombotic

ALX-0081, found to be safe, well tolerated and a potent inhibitor of platelet aggregation

Ablynx has unveiled results from the open label extension of the phase Ib study of its anti-thrombotic, ALX-0081, in patients with stable angina undergoing percutaneous coronary intervention (PCI).

The results supported those of the original phase I study with ALX-0081 and collectively provided proof-of-concept that ALX-0081 is safe and well tolerated and a potent inhibitor of platelet aggregation.

The study was designed to investigate the effect of ALX-0081, which inhibits von Willebrand Factor (vWF), on vWF-mediated clotting, measured using platelet aggregation biomarkers. Additional objectives of the study were to gather data regarding safety and administration.

The study involved a total of 22 patients with stable angina undergoing elective PCI. All patients received standard anti-thrombotic therapy, including aspirin, heparin and plavix, in addition to ALX-0081 (20 patients) or placebo (2 patients).

All 22 patients received four bolus injections of ALX-0081 or placebo every six hours over 24 hours. vWF-mediated platelet aggregation was measured via the biomarker RICO (ristocetin cofactor). All 20 patients who received ALX-0081 experienced complete RICO inhibition, that was statistically significant compared to placebo.

ALX-0081 was safe and well tolerated and did not result in clinically relevant bleeding events. No evidence of anti-drug antibodies was detected up to 30 days after the last injection, said the company.

Professor Jozef Bartunek, primary investigator of the phase Ib study, said: “With the highly statistically significant inhibition of vWF, we have achieved proof-of-concept with the biomarker indicating ALX-0081 is a potent inhibitor of vWF-mediated clotting in patients with stable angina undergoing PCI.”

Edwin Moses, CEO and chairman of Ablynx, said: “We are delighted to see further evidence of efficacy and safety for ALX-0081 in patients with cardiovascular disease. This is a novel target and ALX-0081 could become an important next generation thrombosis treatment. Ablynx recently initiated a Phase II study with ALX-0081 and we look forward to obtaining data from this study by the end of 2010.”